PharmacoEconomics and Outcomes News

Depression "absolutely ripe" for DM in the US
pp. 2-2(1)

UK national service framework for children sends clear message
pp. 2-2(1)

An osteoporosis disease management (DM) programme has been launched in the US by Highmark Blue Cross Blue Shield in conjunction with Merck & Co.
pp. 2-2(1)

New guidelines for the treatment of menopausal symptoms, and the prevention of osteoporosis in women with menopausal symptoms, have been released
pp. 2-2(1)

The cost of improving outcomes in COPD
pp. 3-4(2)

UK pharma demand the right to inform patients directly
pp. 4-4(1)

US FDA's objection to parallel trade "purely economic"
pp. 4-4(1)

Cancer drug costs discussed
pp. 4-4(1)

Ramipril cost effective in patients at high risk for cardiovascular events
pp. 5-5(1)

Cost-related medication underuse fairly common in the US
pp. 5-5(1)

AIDS-related CMV retinitis less prevalent, but still costly
pp. 5-5(1)

Small number of chronic conditions contribute largely to US healthcare spending rise
pp. 6-6(1)

Compliance with consensus guidelines for systemic adjuvant therapy leads to a "significant improvement in survival at 7 years" in women with node-negative breast cancer
pp. 6-6(1)

Naproxen, celecoxib reasonably cost effective for knee OA in Taiwan
pp. 6-6(1)

Linezolid good value in skin and soft tissue infections
pp. 6-6(1)

Employers stand to gain from bupropion for smoking cessation
pp. 7-7(1)

Many patients with frequent episodes of chronic stable angina pectoris do not receive adequate antianginal medications
pp. 7-7(1)

Analgesia requirements for women undergoing medical abortion differ according to certain characteristics
pp. 7-7(1)

Hospitalisation consumes large proportion of costs in IBD
pp. 7-7(1)

Treatment for diabetic leg ulcers costly in the US
pp. 8-8(1)

Escitalopram lowest risk of ADRs = lowest cost in depression
pp. 8-8(1)

Nesiritide reduces resource use in decompensated HF
pp. 8-8(1)

Use of high-dose morphine uncommon in Israeli hospice
pp. 8-8(1)

Resource use frequent among patients with chronic pain
pp. 9-9(1)

Olanzapine confers rapid QOL benefits in bipolar disorder
pp. 9-9(1)

More women using alternative therapies for menopausal symptoms
pp. 9-9(1)

Topiramate reduces alcohol dependence, improves QOL
pp. 10-10(1)

Docetaxel superior choice over mitoxantrone in prostate cancer
pp. 10-10(1)

EORTC QOL instruments valid in malignant pleural mesothelioma
pp. 10-10(1)

OTC omeprazole, amlodipine patent expiry affects US markets
pp. 11-11(1)

US NIH grants funding for ETI 204, genetic research
pp. 11-11(1)

Rofecoxib withdrawal sparks immediate switch to alternatives
pp. 11-11(1)

Pharma market news
pp. 11-11(1)